FDA's Real-Time Trial Data and AI Plan Could Change Biotech Timelines
FDA wants to use real-time data and AI to speed up clinical trials. Here is what the proposal could mean for biotech timelines, capital efficiency, and investors.
How to Use Excel to Organize Clinical Trial Events
Learn how to use Excel to organize biotech clinical trial events, track timelines, and build a simple catalyst calendar.
What Is Combination Therapy?
Learn what combination therapy means in biotech, why it matters in oncology and chronic disease, and how it shapes trial and market strategy.
What Is a Biomarker?
Learn what a biomarker is in biotech, how biomarkers are used in trials, and why biomarker news matters for drug development and investing.
What Is a Surrogate Endpoint?
Learn what a surrogate endpoint is, why it matters in biotech, and how it supports faster regulatory decisions and accelerated approval.
What Is a Secondary Endpoint?
Learn what a secondary endpoint is, how it supports clinical trial interpretation, and why it matters in biotech data releases.
What Is a Primary Endpoint?
Learn what a primary endpoint is, why it matters most in clinical trials, and how investors use it to judge biotech readouts.
What Is an IND and Why Does It Matter in Drug Development?
Learn what an IND is, why it matters in biotech drug development, and how it signals the beginning of human clinical testing.
Drug Development in Biotech: From Discovery to Approval
Learn the full biotech drug development process from discovery to approval, including preclinical work, clinical phases, filing, review, and launch.
Why Biotech Is Especially Well-Suited to Event-Driven Information Products
Learn why biotech is naturally suited to event-driven news products, and why catalysts, timelines, and regulatory milestones create strong product value.
What Does "Catalyst" Mean in Biotech News?
Learn what a catalyst means in biotech news, why catalyst events move stocks, and how investors use catalyst alerts to track trials and FDA milestones.
What Is Interim Data? How It Differs From Final Trial Results
Learn what interim data means in biotech, why companies release it, and how it differs from final clinical trial results and top-line readouts.
What Is Top-Line Data? Why It Shows Up So Often in Biotech Headlines
Learn what top-line data means in biotech, why companies announce it first, and why investors pay close attention to headline clinical results.
What Is Data Lock? Why It Matters Before a Clinical Readout
Learn what data lock means in biotech, why it matters before a clinical readout, and how it affects timing, confidence, and news flow.
What Is a Catalyst Window? Why Timing Matters in Biotech Alerts
Learn what a catalyst window is, why timing matters in biotech news, and how investors use windows to monitor trial, FDA, and earnings events.
Why Biotech News Clusters Around Key Dates
Learn why biotech news clusters around trial timelines, FDA dates, conferences, and earnings, and how investors use those windows to monitor catalysts.
What Is a Phase 3 Data Release? Why It Usually Has the Biggest Impact
Learn what a Phase 3 data release is, why late-stage readouts matter most, and how investors use Phase 3 results to judge approval and launch potential.
What Is a Phase 1 Data Release? Why Early-Stage Readouts Matter
Learn what a Phase 1 data release is, what investors look for in early biotech data, and why first-in-human readouts can shape market sentiment.
What Is a Biotech Catalyst? Why It Matters in Biotech News
Learn what a biotech catalyst is, why catalyst-driven news moves biotech stocks, and how investors use catalyst alerts to follow FDA and clinical events.